Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13680251 | 0.76 | MCL1 (0.50) | MCL1KDM4EMEN1LMNAMAPT | |
| SCHEMBL26330936 | 0.75 | MCL1 (0.31) | MCL1 | |
| SCHEMBL12703489 | 0.75 | KDM4E (0.38) | MCL1KDM4EMEN1LMNAMAPT | |
| SCHEMBL13756087 | 0.68 | MCL1 (0.35) | MCL1KDM4EMEN1LMNAMAPT | |
| SCHEMBL9149426 | 0.65 | ALDH1A1 (0.53) | MCL1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL26331126 | 0.65 | GAA (0.50) | MCL1KDM4EMEN1LMNAMAPT | |
| SCHEMBL24891614 | 0.63 | — | — | |
| SCHEMBL1568646 | 0.63 | — | — | |
| SCHEMBL1747673 | 0.63 | — | — | |
| SCHEMBL12853692 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | MCL1 4841/4885KDM4E 2422/4885MEN1 4480/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | MCL1 2679/4885KDM4E 1068/4885MEN1 4482/4885 |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | INCENP, CYBA, PAICS | MCL1 4839/4885KDM4E 2483/4885MEN1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.